Director/PDMR Shareholding

RNS Number : 1435T

e-Therapeutics plc

16 July 2020

 

E-THERAPEUTICS PLC

("e-therapeutics" or the "Company")

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS

DISCHARGING MANAGERIAL RESPONSIBILITIES

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Ali Mortazavi
2	Reason for the notification
a)	Position/status	Executive Chairman
b)	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	e-therapeutics plc
b)	LEI	21380049RHSSJXWKYT18
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 0.1 pence ISIN:  GB00B2823H99
b)	Nature of the transaction	Purchase of new shares as part of a placing
c)	Price(s) and volume(s)	1,666,666 ordinary shares at a price of 12 pence per share
d)	Aggregated information - Aggregated volume - Price	N/A
e)	Date of the transaction	15 July 2020
f)	Place of the transaction	London Stock Exchange, AIM

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Michael Bretherton
2	Reason for the notification
a)	Position/status	Non-Executive Director
b)	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	e-therapeutics plc
b)	LEI	21380049RHSSJXWKYT18
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 0.1 pence ISIN:  GB00B2823H99
b)	Nature of the transaction	Purchase of new shares  as part of a placing
c)	Price(s) and volume(s)	500,000 ordinary shares at a price of 12 pence per share
d)	Aggregated information - Aggregated volume - Price	N/A
e)	Date of the transaction	15 July 2020
f)	Place of the transaction	London Stock Exchange, AIM

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Trevor Jones
2	Reason for the notification
a)	Position/status	Non-Executive Director
b)	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	e-therapeutics plc
b)	LEI	21380049RHSSJXWKYT18
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 0.1 pence ISIN:  GB00B2823H99
b)	Nature of the transaction	Purchase of new shares as part of a placing
c)	Price(s) and volume(s)	50,000 ordinary shares at a price of 12 pence per share
d)	Aggregated information - Aggregated volume - Price	N/A
e)	Date of the transaction	15 July 2020
f)	Place of the transaction	London Stock Exchange, AIM

For further information, please contact:

e-therapeutics plc Ali Mortazavi, Executive Chairman Laura Roca-Alonso, Chief Business Officer	Tel: [phone] www.etherapeutics.co.uk
Numis Securities Limited Freddie Barnfield/Duncan Monteith ( Nominated Adviser ) James Black (Corporate Broking)	Tel: [phone] www.numis.com
FTI Consulting Simon Conway/Stephanie Cuthbert	Tel: [phone] Email:  [e-mail]

About e-therapeutics plc

e-therapeutics plc is an Oxford, UK-based company with a powerful computer-based approach to drug discovery, founded on its industry-leading expertise in network biology to fully capture disease complexity. The Company combines network science, machine learning, artificial intelligence, statistics and access to big data with expertise in drug discovery and development to transform the search for new medicines and intervention strategies.

e-therapeutics has developed an in silico laboratory that enables the rapid screening of millions of compounds and the identification of small sub-sets that are enriched for highly active hits. Its proprietary platform also has novel applications in functional genomics, being able to analyse complex genetic datasets, provide a deep understanding of pathological mechanisms and distil actionable insights for the discovery of novel drugs, biomarkers and diagnostics.

e-therapeutics has deployed and validated its disease-agnostic drug discovery platform both in house and with partners, including Novo Nordisk, Galapagos NV and a US-based, top 5 pharmaceutical company.

 

END

 

 

DSHFLFIADDIELII